Sulfasalazine, 500 mg 50 pcs

Sulfasalazine selectively accumulates in the intestinal connective tissue with the release of 5-aminosalicylic acid (5-ASA), which has anti-inflammatory activity, and sulfapyridine, which has antimicrobial bacteriostatic activity.

Indications

• Ulcerative colitis (treatment of exacerbations and maintenance therapy in remission);
• Crohn’s disease (mild and moderate forms in the acute phase);
• Rheumatoid arthritis; juvenile rheumatoid arthritis with ineffectiveness of non-steroidal anti-inflammatory drugs (NSAIDs).

Pharmacological effect

Sulfasalazine selectively accumulates in the connective tissue of the intestine with the release of 5-aminosalicylic acid (5-ASA), which has anti-inflammatory activity, and sulfapyridine, which has antimicrobial bacteriostatic activity.

Special instructions

Use with caution in patients with impaired liver and/or kidney function, patients with bronchial asthma, allergic reactions.

During treatment, it is recommended to drink increased amounts of fluid.

During treatment, the level of liver enzymes, general blood and urine tests should be monitored.

Active ingredient

Sulfasalazine

Composition

1 tablet contains the active substance: sulfasalazine – 500.0 mg

Contraindications

• Hypersensitivity to sulfasalazine or other components of the drug, as well as sulfonamides or salicylates;
• porphyria;
• granulocytopenia;
• aplastic anemia;
• congenital deficiency of glucose-6-phosphate dehydrogenase (risk of developing jaundice);
• liver and/or kidney failure;
• children under 10 years of age and/or weighing 35 kg or less, with chronic inflammatory bowel diseases (for this dosage form and dosage);
• obstruction of the intestines or urinary tract;
• children under 6 years of age with juvenile rheumatoid arthritis (efficacy and safety have not been established);
• breastfeeding period.

Side Effects

From the nervous system: headache, dizziness, tinnitus, ataxia, convulsions, sleep disturbances, hallucinations, peripheral neuropathy.

From the urinary system: renal dysfunction, interstitial nephritis.

From the digestive system: nausea, vomiting, diarrhea, abdominal pain, anorexia, hepatitis, pancreatitis.

From the respiratory system: interstitial pneumonitis and other lesions of the lung tissue.

From the hematopoietic system: anemia, leukopenia, thrombocytopenia, agranulocytosis.

From the reproductive system: transient oligospermia, infertility.

Allergic reactions: skin rash, toxic epidermal necrolysis, malignant exudative erythema, fever, anaphylactic shock.

Other: possible yellow coloration of skin, urine, soft contact lenses.

Interaction

Enhances the effect of anticoagulants, antiepileptic and oral hypoglycemic drugs, as well as the side effects of cytostatics, immunosuppressants, hepato- and nephrotoxic drugs.

When used simultaneously with sulfasalazine, the toxicity of azathioprine and mercaptopurine increases.

When used simultaneously with ampicillin or rifampicin, the release of 5-aminosalicylic acid from the sulfasalazine molecule in the colon is reduced (due to the suppression under the influence of ampicillin and rifampicin of the activity of anaerobic bacteria, with the participation of which this process occurs). In this regard, the effectiveness of sulfasalazine may be reduced. It is believed that the interaction of sulfasalazine with neomycin manifests itself in the same way.

When used simultaneously with digoxin, its absorption may be reduced; with talinolol – absorption of talinolol decreases; with folic acid – the absorption of folic acid may be reduced.

Manufacturer

Ozon, Russia